Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/11/2010

QUITYCurrent liabilities:Current portion of long-term debt

$   2,666,668$
9,061,973Current portion of other long-term obligations

12,035144,828Accounts payable

3,416,3705,632,796Other accrued liabilities

3,817,8223,784,777Total current liabilities

9,912,89518,624,374Revolving line of credit

1,825,9511,825,951Long-term debt, excluding current portion

3,333,3328,938,027Other long-term obligations, excluding current portion

211,757184,632Total liabilities

15,283,93529,572,984Commitments and contingenciesRedeemable common stock

-1,930,000Equity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,353,849 and 20,180,486(1) shares issued and outstandingas of September 30, 2010 and December 31, 2009, respectively

68,521,47067,711,746Retained earnings

6,161,2524,542,126Total shareholders' equity

74,682,72272,253,872Noncontrolling interests

(56,791)(32,536)Total equity

74,625,93172,221,336Total liabilities and equity

$ 89,909,866$  103,724,320(1) Number of shares issued and outstanding represent total shares of common stock regardless of classification on the consolidated balance sheet. The number of shares of redeemable common stock at December 31, 2009 was 142,016.CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income
(Unaudited)Three months ended September 30,Nine months ended September 30,2010200920102009Net revenues

$
2,190,870$
3,597,760$
33,061,457$
32,822,972Costs and expenses:Cost of products sold

909,4341,761,0692,632,4473,271,363Selling and marketing

5,692,0486,087,80717,147,68314,611,796Research and development

1,138,955640,8772,947,6234,041,719General and administrative

1,806,9752,537,6275,471,0125,218,925Amortization of productlicense right

171,732171,726515,184515,178Other

27,86926,59583,283
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
4. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
7. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
8. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
9. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
10. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... The U.S. Food and Drug Administration,s (FDA) ... decided today that it could not recommend approval ... the currently available data (13-3); but, voted unanimously ... a reader training program that demonstrates reader accuracy ...
... Medical Simulation Corporation (MSC) will highlight a ... providers at the 2011 International Meeting on Simulation ... MSC,s full-service simulation training and education services are ... all healthcare providers. MSC,s complete line of equipment ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare 2
(Date:9/22/2014)... On Tuesday, September 16th, 2014, at 8:00 p.m. ... “KC After Dark.” Hosted by top WRNW1 host, ... every Tuesday at 8:00 p.m. EST. WRNW1 had a promotion ... and because of the amazing turnout for their first show, ... 500 callers. , During this comical, yet professional show, ...
(Date:9/22/2014)... September 22, 2014 The Philadelphia 100, ... Greater Philadelphia region each year, is considered a hallmark ... manufacturer MK Precision is proud to announce it has ... MK Precision will attend the Philadelphia 100 ... the premiere business events of the year, as well ...
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... Amy Norton HealthDay Reporter ... may fare better when newborn intensive care units (NICU) set ... infants, a new study finds. Researchers at one children,s ... and were less distressed when their NICU switched from the ... findings, published online Sept. 22 in the journal Pediatrics ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2
... The Autism Research Institute states that many of those ... appropriately diagnosed and treated may result in marked improvementATLANTA, ... every 20 seconds in the US. Autism is ... AIDS combined. The Federal Centers for Disease Control ...
... SANTA MONICA, Calif., April 6 Cord Blood America, Inc. ... preservation company ( http://www.cordblood-america.com ) ... to families nationwide and internationally, is pleased to announce that ... long term debt by approximately $750,000, or 12 percent. ...
... place in line at local emergency departments and ... has selected Trevelino/Keller Communications Group, Inc., one of ... launch the company nationally and build out its ... Alabama and Florida -- as it pursues national ...
... a systemic disease or an autoimmune disorder in which the ... of cells called the synovium that lines and lubricates the ... and crippling stiffness, particularly of the hands and feet. It ... mobility and quality of life. RA cannot be confirmed or ...
... solutions provider, is pleased to announce that its entire suite of ... , ... Charlotte, NC (PRWEB) April 6, 2009 -- IQMax, ... that its entire suite of healthcare solutions is available on Blackberry® ...
... high blood pressure and heart disease during a clinical trial for osteoarthritis. ... ... Company, a Bendigo based company who manufactures a topical pain relief lotion ... trial for their flagship product, Elmore Oil., , ,The trial was headed ...
Cached Medicine News:Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 3Health News:IQMax Delivers Healthcare Solutions to Blackberry Devices 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
...
Medicine Products: